Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock surged by 13.05% on Monday to $19.14 after receiving a higher price target from Wells Fargo. The firm raised the target to $29, citing optimism about the company's potential treatment for rare kidney diseases.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing